BioSpace News Archive

Drug Development

CymaBay Therapeutics Reaches Target Enrollment in the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis ENHANCE on track to complete full enrollment earlier than projected

CymaBay Therapeutics, Inc. announced achievement of the targeted 240 patient enrollment goal for ENHANCE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary Cholangitis CymaBay is on track to complete full enrollment by the end of November.

November 4, 2019
·
4 min read
BioCapital

March of Dimes 2019 Report Card Shines Spotlight on the U.S. Maternal and Infant Health Crisis

New Expanded Report Examines State of Maternal and Infant Health in States and Cities across the Country; Outlines Actions Needed to Improve Health Outcomes for Moms and Babies

November 4, 2019
·
6 min read
Drug Development

First Patient Screened for RhoVac’s Clinical Phase IIb-study

RhoVac AB announces, on 4th November 2019, that the first patient has been screened for the company’s clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 The screening took place at the Odense University Hospital.

November 4, 2019
·
2 min read
Biotech Bay

PQ Bypass Initiates Pivotal Study of Next-Generation Advancement in Stent Graft Technology for Treatment of Patients with Peripheral Artery Disease

PQ Bypass, Inc. announced it has enrolled the first patient in its TORUS 2 multi-center clinical trial of its self-expanding TORUS® stent graft system, a novel technology designed for the treatment of peripheral artery disease in the superficial femoral artery This inaugural enrollment comes less than a month after the study received unconditional approval from the FDA for the TORUS 2 original IDE.

November 4, 2019
·
4 min read
Pharm Country

Seven Data Presentations Relevant to Vascepa® Capsules and Persistent Cardiovascular Risk to be Presented at American Heart Association’s 2019 Scientific Sessions, November 16 – 18Amarin to Webcast Discussion of Presented Data November

Amarin Corporation plc, a pharmaceutical company focused on improving cardiovascular health, announced that two independently conducted studies, two moderated poster sessions and three presentations based on research supported by Amarin will be presented at the American Heart Association’s 2019 Scientific Sessions, November 16-18, in Philadelphia, PA.

November 4, 2019
·
14 min read
Deals

Amulet Capital’s OPEN Health Merges with Pharmerit International

Transaction creates the leading provider of HEOR, market access, medical affairs and healthcare communications services to pharmaceutical companies across US, Europe and Asia

November 4, 2019
·
4 min read
Picosun Expands Selection of Biocompatible ALD Materials for Medical Applications

Picosun Group, the leading supplier of AGILE ALD® thin film coating solutions for global industries, expands its selection of biocompatible ALD materials to be used in medical applications.

November 4, 2019
·
4 min read
Biotech Bay

Eighth Annual Breakthrough Prize -- “The Oscars of Science” -- Celebrates Top Achievements in Life Sciences, Physics & Mathematics; Awards Over $21 Million in Prizes at Gala Televised Ceremony in Silicon Valley

2019 Special Breakthrough Prize in Fundamental Physics Awarded to Sergio Ferrara, Daniel Z. Freedman and Peter van Nieuwenhuizen

November 4, 2019
·
15 min read
Business

Vifor Pharma Enters Into Commercial Collaboration in the US with Janssen

Agreement to jointly commercialise the new diabetic kidney disease (DKD) indication for INVOKANA® (canagliflozin) in the US

November 4, 2019
·
3 min read
Calliditas Therapeutics Capital Markets Day Today November 4

Calliditas Therapeutics hosts a Capital Markets Day in Stockholm, moderated by Lars Frick from Börsveckan.

November 4, 2019
·
2 min read